Drug Profile
EA 230
Alternative Names: EA-230; Peptide 46; Peptide EA 230Latest Information Update: 16 Feb 2021
Price :
$50
*
At a glance
- Originator Exponential Biotherapies
- Class Anti-inflammatories; Antiseptics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Renal failure
- No development reported Systemic inflammatory response syndrome
Most Recent Events
- 16 Feb 2021 No development reported - Phase-II for Systemic inflammatory response syndrome in Netherlands (IV) (Exponential Biotherapies pipeline, February 2021)
- 12 Sep 2018 Exponential Biotherapies completes a phase II trial in Systemic inflammatory response syndrome in Netherlands (NCT03145220)
- 17 Jul 2016 Phase-II/III clinical trials in Renal failure (Prevention) in Netherlands (IV) (EudraCT2014-002481-78)